Cabaletta Bio CABA Stock
Cabaletta Bio Price Chart
Cabaletta Bio CABA Financial and Trading Overview
| Cabaletta Bio stock price | 13 USD |
| Previous Close | 12.96 USD |
| Open | 12.88 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 800 |
| Day's Range | 12.6 - 13.66 USD |
| 52 Week Range | 0.59 - 13.66 USD |
| Volume | 304.72K USD |
| Avg. Volume | 331.06K USD |
| Market Cap | 510.85M USD |
| Beta (5Y Monthly) | 2.537515 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.65 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.17 USD |
CABA Valuation Measures
| Enterprise Value | 317.2M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.9937887 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.4015045 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.587 |
Trading Information
Cabaletta Bio Stock Price History
| Beta (5Y Monthly) | 2.537515 |
| 52-Week Change | 1149.51% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 13.66 USD |
| 52 Week Low | 0.59 USD |
| 50-Day Moving Average | 10.58 USD |
| 200-Day Moving Average | 6.87 USD |
CABA Share Statistics
| Avg. Volume (3 month) | 331.06K USD |
| Avg. Daily Volume (10-Days) | 297.79K USD |
| Shares Outstanding | 39.69M |
| Float | 22.12M |
| Short Ratio | 8.59 |
| % Held by Insiders | 10.98% |
| % Held by Institutions | 76.35% |
| Shares Short | 4.02M |
| Short % of Float | 11.58% |
| Short % of Shares Outstanding | 10.11% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -33.45% |
| Return on Equity (ttm) | -56.34% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -56772000 USD |
| Net Income Avi to Common (ttm) | -55883000 USD |
| Diluted EPS (ttm) | -1.86 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 93.85M USD |
| Total Cash Per Share (mrq) | 2.99 USD |
| Total Debt (mrq) | 4.67M USD |
| Total Debt/Equity (mrq) | 5.1 USD |
| Current Ratio (mrq) | 10.288 |
| Book Value Per Share (mrq) | 2.924 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -46179000 USD |
| Levered Free Cash Flow (ttm) | -29580000 USD |
Profile of Cabaletta Bio
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | 2929 Arch Street |
| ZIP | 19104 |
| Phone | 267 759 3100 |
| Website | https://www.cabalettabio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 66 |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Cabaletta Bio Stock
What is a current CABA stock price?
Cabaletta Bio CABA stock price today per share is 13 USD.
How to purchase Cabaletta Bio stock?
You can buy CABA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cabaletta Bio?
The stock symbol or ticker of Cabaletta Bio is CABA.
Which industry does the Cabaletta Bio company belong to?
The Cabaletta Bio industry is Biotechnology.
How many shares does Cabaletta Bio have in circulation?
The max supply of Cabaletta Bio shares is 63.2M.
What is Cabaletta Bio Price to Earnings Ratio (PE Ratio)?
Cabaletta Bio PE Ratio is now.
What was Cabaletta Bio earnings per share over the trailing 12 months (TTM)?
Cabaletta Bio EPS is -1.65 USD over the trailing 12 months.
Which sector does the Cabaletta Bio company belong to?
The Cabaletta Bio sector is Healthcare.
Cabaletta Bio CABA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}